ASLAN PHARMACEUTICALS LIMITED (a company incorporated in the Cayman Islands) 5,124,527 American Depositary Shares Representing 25,622,635 Ordinary Shares (par value NT$ 10.00 per share) UNDERWRITING AGREEMENTUnderwriting Agreement • December 5th, 2019 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations • New York
15,000,000 American Depositary Shares Representing 75,000,000 Ordinary Shares (Nominal Value $0.01 Per Share) ASLAN Pharmaceuticals Limited UNDERWRITING AGREEMENTUnderwriting Agreement • March 4th, 2021 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • October 9th, 2020 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations • New York
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 13th, 2024 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”), dated as of March 12, 2024, is between ASLAN Pharmaceuticals Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
FORM OF WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES ASLAN Pharmaceuticals LimitedWarrant Agreement • March 13th, 2024 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations
THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”), issued in the form of uncertificated securities, certifies that, for value received, ______ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on ______, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from ASLAN Pharmaceuticals Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), up to ______ Ordinary Shares, nominal or par value $0.01 per share (as subject to adjustment hereunder) (the “Warrant Shares”), represented by _________ American Depositary Shares (“ADSs”), each twenty-five (25) Ordinary Shares represented by one (1) ADS (as subject to adjustment hereunder) (the “Warrant AD
INDEMNITY AGREEMENTIndemnification Agreement • April 16th, 2018 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations • California
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , 2018, is made by and between , an exempted company incorporated in the Cayman Islands (the “Company”), and (“Indemnitee”).
DATED THIS 10th DAY OF OCTOBER 2016 Between NANYANG TECHNOLOGICAL UNIVERSITY And ASLAN PHARMACEUTICALS PTE LTD LICENSING AND RESEARCH COLLABORATION AGREEMENTLicensing and Research Collaboration Agreement • March 26th, 2018 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations
WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES [OR PRE-FUNDED WARRANTS] ASLAN PHARMACEUTICALS LIMITEDSecurity Agreement • February 24th, 2023 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations
THIS WARRANT TO PURCHASE (A) ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES [OR (B) PRE-FUNDED WARRANTS TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES] (the “Warrant”), issued in the form of uncertificated securities, certifies that, for value received, [_____________] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date (as defined below) and on or prior to 5:00 p.m. (New York City time) on the Warrant Exercise Deadline (as defined below) but not thereafter (such period of time between the date of the Issue Date and the Warrant Exercise Deadline, the “Exercise Period”), to subscribe for and purchase from ASLAN Pharmaceuticals Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), up to [____] Ordinary Shares, nominal or par value $0.01 per share (as subject to a
AMENDED DEVELOPMENT AND LICENSE AGREEMENT By and between ALMIRALL, S.A. and ASLAN PHARMACEUTICALS PTE. LTD. Dated: December 21, 2015Development and License Agreement • March 26th, 2018 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations
This AMENDED DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”), dated as of December 21, 2015 (“Effective Date”), is entered by and between ALMIRALL, S.A. (“ALMIRALL”), a Spanish corporation having its principal offices at Ronda de General Mitre, 151, 08022 Barcelona, Spain, and ASLAN PHARMACEUTICALS Pte. Ltd. (“ASLAN”), a Singapore corporation having its principal offices at 10A Bukit Pasoh Road, Singapore 089824. ALMIRALL and ASLAN shall be referred to individually as a “Party” and collectively as the “Parties”.
LICENSE AGREEMENTLicense Agreement • March 26th, 2018 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations • England and Wales
This License Agreement (this “Agreement”), entered into as of January 3rd, 2018 (the “Effective Date”), is made by and between Array BioPharma Inc., a Delaware corporation, having offices at 3200 Walnut Street, Boulder, Colorado 80301, and ASLAN Pharmaceuticals Pte. Ltd., a Singapore corporation, with offices at 83 Clemenceau Avenue #12-03 UE Square, Singapore 239920.
ContractLicense Agreement • April 29th, 2019 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE ASLAN PHARMACEUTICALS PTE LTD. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ASLAN PHARMACEUTICALS PTE LTD. IF PUBLICLY DISCLOSED.
LICENCE AGREEMENT BETWEEN CSL LIMITED ABN 99 051 588 348 AND ASLAN Pharmaceuticals Pte LtdLicense Agreement • March 26th, 2018 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations • England
Now, therefore, in consideration of the premises and mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:
ContractWarrant Agreement • May 31st, 2024 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations • New York
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY U.S. STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
COLLABORATIVE DEVELOPMENT & COMMERCIALISATION AGREEMENT RELATING TO EBLASAKIMAB IN JAPANCollaborative Development & Commercialisation Agreement • April 12th, 2024 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations • England
ASLAN Pharmaceuticals Pte. Ltd. (“ASLAN”), incorporated and registered in Singapore with company number 201007695N, having its principal offices at 3 Temasek Avenue, Level 18, Centennial Tower, Singapore 039190; and
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 25th, 2021 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of February 24, 2021 (the “Effective Date”), among ASLAN Pharmaceuticals Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), and each purchaser identified on Exhibit A attached hereto (each a “Purchaser” and collectively the “Purchasers”). The Company and the Purchasers are sometimes each referred to herein as a “Party” and collectively as the “Parties.”
WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES [OR PRE-FUNDED WARRANTS] ASLAN PHARMACEUTICALS LIMITEDSecurities Agreement • February 24th, 2023 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations
THIS WARRANT TO PURCHASE (A) ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES [OR (B) PRE-FUNDED WARRANTS TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES] (the “Warrant”), issued in the form of uncertificated securities, certifies that, for value received, [_____________] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date (as defined below) and on or prior to 5:00 p.m. (New York City time) on the Warrant Exercise Deadline (as defined below) but not thereafter (such period of time between the date of the Issue Date and the Warrant Exercise Deadline, the “Exercise Period”), to subscribe for and purchase from ASLAN Pharmaceuticals Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), up to [____] Ordinary Shares, nominal or par value $0.01 per share (as subject to a
AMENDMENT NO. 1 TO WARRANT TO PURCHASE ORDINARY SHARESWarrant to Purchase Ordinary Shares • July 3rd, 2023 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations • New York
THIS AMENDMENT NO. 1 TO WARRANT TO PURCHASE ORDINARY SHARES is made this 30th day of June, 2023, by and between K2 HealthVentures Equity Trust LLC (“Holder”) and ASLAN Pharmaceuticals Limited, a Cayman Islands exempted company with registration number 289175 (the “Company”).
AMENDMENT NO. 2 TO THE OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • April 12th, 2024 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations
This Amendment No. 2 to the Open Market Sale AgreementSM (this “Amendment No. 2”) is entered into as of the date first written above by ASLAN Pharmaceuticals Limited, an exempted company incorporated with limited liability in the Cayman Islands (the “Company”), and Jefferies LLC (“Agent”), which are parties to that certain Open Market Sale AgreementSM, dated October 9, 2020 (the “Original Agreement”), as amended on September 13, 2022 (the “Amendment No. 1” and collectively with the Original Agreement, the “Sale Agreement”). All capitalized terms not defined herein shall have the meanings ascribed to them in the Sale Agreement. The parties, intending to be legally bound, hereby amend the Sale Agreement as follows:
SECOND Amendment to Loan, Guaranty and security agreementLoan, Guaranty and Security Agreement • December 8th, 2023 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations • New York
This Second Amendment to Loan, Guaranty, and Security Agreement (this “Amendment”) is entered into this 6th day of December, 2023, by and among (a) ASLAN PHARMACEUTICALS (USA) INC., a Delaware corporation (“Borrower Representative”), ASLAN PHARMACEUTICALS LIMITED, an exempted company incorporated under the laws of the Cayman Islands and each other Person party hereto as a borrower from time to time (“Parent”, and together with Borrower Representative, collectively, “Borrowers”, and each, a “Borrower”), (b) ASLAN PHARMACEUTICALS PTE. LTD., a private company limited by shares formed under the laws of the Republic of Singapore (“ASLAN LTD” and together with each other Person party hereto or any other Loan Documents as a guarantor from time to time, collectively, “Guarantors” and each, a “Guarantor”, and together with Borrowers, collectively, “Loan Parties”, and each, a “Loan Party”), (c) K2 HEALTHVENTURES LLC as a lender, and the other lenders from time to time party hereto (collectively,
AMENDMENT NO. 1 TO THE OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • September 13th, 2022 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations • New York
This Amendment No. 1 to the Open Market Sale AgreementSM (this “Amendment”) is entered into as of the date first written above by ASLAN Pharmaceuticals Limited, an exempted company incorporated with limited liability in the Cayman Islands (the “Company”), and Jefferies LLC (“Agent”), that are parties to that certain Open Market Sale AgreementSM, dated October 9, 2020 (the “Original Agreement”). All capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreement. The parties, intending to be legally bound, hereby amend the Original Agreement as follows:
AMENDMENT AGREEMENT No. 1 TO LICENCE AGREEMENT BETWEEN CSL LIMITED ABN 99 051 588 348 AND ASLAN Pharmaceuticals Pte LtdLicence Agreement • January 9th, 2019 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations
FIRST AMENDMENT TO LOAN, GUARANTY AND SECURITY AGREEMENTLoan, Guaranty and Security Agreement • July 3rd, 2023 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations • New York
This First Amendment to Loan, Guaranty, and Security Agreement (this “Amendment”) is entered into this 30th day of June, 2023, by and among (a) ASLAN PHARMACEUTICALS (USA) INC., a Delaware corporation (“Borrower Representative”), ASLAN PHARMACEUTICALS LIMITED, an exempted company incorporated under the laws of the Cayman Islands and each other Person party hereto as a borrower from time to time (“Parent”, and together with Borrower Representative, collectively, “Borrowers”, and each, a “Borrower”), (b) ASLAN PHARMACEUTICALS PTE. LTD., a private company limited by shares formed under the laws of the Republic of Singapore (“ASLAN LTD” and together with each other Person party hereto or any other Loan Documents as a guarantor from time to time, collectively, “Guarantors” and each, a “Guarantor”, and together with Borrowers, collectively, “Loan Parties”, and each, a “Loan Party”), (c) K2 HEALTHVENTURES LLC as a lender, and the other lenders from time to time party hereto (collectively, “Le
Deed of Amendment and RestatementLicence Agreement • June 17th, 2019 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations • England
The parties set out in Schedule 1 (as the “Lenders”) and ASLAN Pharmaceuticals Limited (as the “Borrower”) LOAN FACILITY AGREEMENTLoan Facility Agreement • October 31st, 2019 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations
PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES ASLAN PHARMACEUTICALS LIMITEDSecurities Agreement • February 24th, 2023 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations
THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (this “Warrant”), issued in the form of uncertificated securities, certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from ASLAN Pharmaceuticals Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), up to [____] Ordinary Shares, nominal or par value $0.01 per share (as subject to adjustment hereunder, the “Warrant Shares”), represented by [____] American Depositary Shares (“ADSs”), each five (5) Ordinary Shares represented by one (1) ADS, as subject to adjustment hereunder (the “Warrant ADSs”). The purchase p
LOAN, GUARANTY, AND SECURITY AGREEMENTLoan, Guaranty, and Security Agreement • July 14th, 2021 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations • New York
This LOAN, GUARANTY, AND SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of July 12, 2021 (the “Closing Date”) is entered into among (a) ASLAN PHARMACEUTICALS (USA) INC., a Delaware corporation (“Borrower Representative”), ASLAN PHARMACEUTICALS LIMITED, an exempted company incorporated under the laws of the Cayman Islands and each other Person party hereto as a borrower from time to time (“Parent”, and together with Borrower Representative, collectively, “Borrowers”, and each, a “Borrower”), (b) ASLAN PHARMACEUTICALS PTE. LTD., a private company limited by shares formed under the laws of the Republic of Singapore (“ASLAN LTD” and together with each other Person party hereto or any other Loan Documents as a guarantor from time to time, collectively, “Guarantors” and each, a “Guarantor”, and together with Borrowers, collectively, “Loan Parties”, and each, a “Loan Party”), (c) K2 HEALTHVENTURES LLC and any other le
The parties set out in Schedule 1 (as the “Lenders”) and ASLAN Pharmaceuticals Limited (as the “Borrower”) LOAN FACILITY AGREEMENTLoan Facility Agreement • October 31st, 2019 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations
THIRD Amendment and forbearance to Loan, Guaranty and security agreementLoan, Guaranty and Security Agreement • May 31st, 2024 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations • New York
This Third Amendment and Forbearance to Loan, Guaranty, and Security Agreement (this “Amendment”) is entered into this 29th day of May, 2024, by and among (a) ASLAN PHARMACEUTICALS (USA) INC., a Delaware corporation (“Borrower Representative”), ASLAN PHARMACEUTICALS LIMITED, an exempted company incorporated under the laws of the Cayman Islands and each other Person party hereto as a borrower from time to time (“Parent”, and together with Borrower Representative, jointly, severally, and collectively, “Borrowers”, and each, a “Borrower”), (b) ASLAN PHARMACEUTICALS PTE. LTD., a private company limited by shares formed under the laws of the Republic of Singapore (“ASLAN LTD” and together with each other Person party hereto or any other Loan Documents as a guarantor from time to time, collectively, “Guarantors” and each, a “Guarantor”, and together with Borrowers, collectively, “Loan Parties”, and each, a “Loan Party”), (c) K2 HEALTHVENTURES LLC as a lender, and the other lenders from time
ContractWarrant Agreement • July 14th, 2021 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations • New York
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY U.S. STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
ContractLoan Facility Agreement • October 31st, 2019 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations
We refer to the Loan Agreement which we have entered into on today’s date. Terms defined in the Loan Agreement shall have the same meanings herein except where otherwise expressly indicated. This Letter Agreement (“this Agreement”) sets out additional terms to those applying in the Loan Agreement, such additional terms being between the Borrower and the Lender only. This Agreement shall be regarded as supplemental to the Loan Agreement and shall be read and construed in conjunction with the Loan Agreement.
UNIT PURCHASE AGREEMENTUnit Purchase Agreement • February 24th, 2023 • ASLAN Pharmaceuticals LTD • Pharmaceutical preparations • New York
This Unit Purchase Agreement (this “Agreement”) is dated as of February 24, 2023, by and among ASLAN Pharmaceuticals Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
